Genes & CellsGenes & CellsГены и КлеткиGenes and Cells2313-18292500-2562Human Stem Cells Institute12164110.23868/gc121641ArticlesСтатьиCurrent situation and prospects for cell therapy of the cerebral palsyСовременное состояние и перспективыклеточной терапии детского церебрального параличаGrigoryanA SГригорянА С

Human Stem Cell Institute, Moscow

Институт Стволовых Клеток Человека, Москва

Human Stem Cell Institute, MoscowИнститут Стволовых Клеток Человека, Москва1506201272NO2 (2012)№2 (2012)717411012023Copyright ©; 2012, Eco-VectorCopyright ©; 2012, Эко-Вектор2012Eco-VectorЭко-Векторhttps://genescells.ru/2313-1829/article/view/121641

Cerebral palsy is pathological condition caused by the irreversible damage or dysembryogenesis of the brain. Today there is no effective therapy of the patients suffering from cerebral palsy, and the researchers and clinicists have to search the alternative methods of treatment. Cell therapy with the use of different types of stem cells is the promising yet not well-examined approach to the correction of the status of patients. In this review the possible future methods of stem cell therapy of cerebral palsy are discussed.

Детский церебральный паралич (ДЦП) - патологиче- ское состояние, вызванное необратимыми повреждениями или нарушениями эмбриогенеза головного мозга. В на- стоящее время не существует эффективной терапии паци- ентов с ДЦП, в связи с чем исследователи и клиницисты вынуждены вести поиск альтернативных методов лечения. Клеточная терапия при помощи различных типов стволо- вых клеток - перспективный, однако на сегодняшний день слабо изученный подход к коррекции состояния больных. В обзоре обсуждаются возможные направления клеточной терапии, которые могли бы применяться по поводу ДЦП в будущем.

Pharoah P.O. Epidemiology of cerebral palsy: a review. J. Royal Society Med. 1981; 74(7): 516-20.Westbom L., Hagglund G., Nordmark E. Cerebral palsy in a total population of 4-11 year olds in southern Sweden. Prevalence and distribution according to different CP classification systems. BMC pediatrics 2007; 7: 41.Мастюкова Е.М. Дети с церебральным параличом. В: Лубов- ский В.И., редактор. Специальная психология. М.; 2003.OShea T.M. Diagnosis, treatment, and prevention of cerebral palsy. Clinical obsterics and gynecology 2008; 51(4): 816-28.Lindvall O., Kokaia Z. Progress stem cells for the treatment of neurological disorders. Nature 2006; 441: 1094-6.Imnitola J. Prospects for neural stem cell-based therapies for neurological diseases. Neurotherapeutics 2007; 4(4): 701-14.Harting M.T., Sloan L.E., Jimenez F. et al. Subacute neural stem cell therapy for traumatic brain injury. J. Surg. Res. 2009; 153(2): 188-94.Gonzalez R., Teng Y.D., Park K.I. et al. Neural stem cells: therapeutic applications in neurodegenerative disorders. Handbook of Stem Cells 2004; 687-99.Wilkins A., Kemp K., Ginty M. et al. Human bone marrowderived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res. 2009; 3(1): 63-70.Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J. Clinical Neurosci. 2009; 16(1): 12-20.Crigler L., Robey R., Asawachaicharn A. et al. Human mesenchymal stem cell subpopulations express a variety of neuroregulatory molecules and promote neuronal cell survival and neuritogenesis. Exp. Neurol. 2006; 198(1): 54-64.Harris D.T. Cord blood stem cells: a review on potential neurological applications. Stem Cells Rev. 2008; 4(4): 269-74.Garbuzova-Davis S., Willing A.E., Zigova T. et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: Distribution, migration, and differentiation. J. Hematother. Stem Cell Res. 2003; 12: 255-7Lu D., Sanberg P.R., Mahmood A. et al. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant. 2004; 11: 275-81.Chen J., Sanberg P.R., Li Y. et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001; 32: 2682-8.Newman M.B., Davis C.D., Kuzmin-Nichols N., Sanberg P.R. Human umbilical cord blood (HUCB) cells for central nervous system repair. Neurotox. Res. 2003; 5: 355-68.Селедцов В.И., Кафанова М.Ю., Рабинович С.С. и соавт. Клеточная терапия детского церебрального паралича. Клет. Тех. Биол. Мед. 2005; 2: 84-8.http://www.rp-online.de/region-duesseldorf/duesseldorf/ nachrichten/stammzell-klinik-xcell-muss-schliessen-1.1212066Bartley J., Carroll J.E. Stem cell therapy for cerebral palsy. Expert. Opin. Biol. Ther. 2003; 3(4): 541-9.Yasuhara T., Matsukawa N., Yu G. et al. Transplantation of cryopreserved human bone marrow-derived multipotent adult progenitor cells for neonatal hypoxic-ischemic injury: targeting the hippocampus. Rev. Neurosci. 2006; 17(1-2): 215-25.Yasuhara T., Matsukawa N., Yu G. et al. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant. 2006; 15(3): 231-8.Yasuhara T., Hara K., Maki M. et al. Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J. Cereb. Blood Flow Metab. 2008; 28(11): 1804-10.Bicknese A., Goodwin H., Quinn C. et al. Human umbilical cord blood cells can be induced to express markers for neurons and glia. Cell Transplant. 2002; 11: 261-4.McGuckin C.P., Forraz N., Allouard O., Pet-Tengell R. Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro. Exp. Cell. Res. 2004; 295: 350-9.Taguchi A., Soma T., Tanaka H. et al. Administration of CD34+ cells after stroke enhances neurogenesis and angiogenesis in a mouse model. J. Clin. Invest. 2004; 114: 330-8.Buschmann I.R., Hoefer I.E., VanRoyen N. et al. GM-CSF: A strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001; 159: 343-56.Ramirez F., Steenblock D.A., Payne A.G., Darnall L. Umbilical cord stem cell therapy for cerebral palsy. Med. Hypoth. Res. 2006; 3: 679-86.Choi E-K., Park D., Kim T.K. et al. Animal models of periventricular leukomalacia. Lab. Anim. Res. 2011; 27(2): 77-84.Girard S., Kadhim H., Beaudet N. et al. Developmental motor deficits induced by combined fetal exposure to lipopolysaccharide and early neonatal hypoxia/ischemia: A novel animal model for cerebral palsy in very premature infants. Neuroscience 2009; 158(2): 673-82.Robertson R., Woodard J.E., Toso L. Postnatal inflammatory rat model for cerebral palsy: Too different from humans. Amer. J. Obstetr. Gynecol. 2006; 195(4): 1038-44.Toso L., Poggi S., Park J. et al. Inflammatory-mediated model of cerebral palsy with developmental sequelae. Amer. J. Obstetr. Gynecol. 2005; 3(S1): 933-41.Newman M.B., Davis C.D., Borlongan C.V. et al. Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin. Biol. Ther. 2004; 4: 121-30.